ESR1 and cancer: The RP2D of 120 mg/day palazestrant demonstrated evidence of antitumor activity, with a CBR of 45.7% and a median PFS of 4.8 months in the overall population and a CBR of 58.6% and a median PFS of 5.6 months among patients with cancers with ESR1 mutations at baseline.